Clinical Trial Update: A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline [Phase 3]

View source ↗

Summary

A completed Phase 3 placebo-controlled trial evaluating the safety of varenicline for smoking cessation over 52 weeks.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• Varenicline (varenicline)

Snippet

Sponsor: Pfizer | Conditions: Smoking Cessation | Phase 3 | Status: COMPLETED